231 related articles for article (PubMed ID: 17455910)
1. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
Reigan P; Colucci MA; Siegel D; Chilloux A; Moody CJ; Ross D
Biochemistry; 2007 May; 46(20):5941-50. PubMed ID: 17455910
[TBL] [Abstract][Full Text] [Related]
2. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D
Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
Colucci MA; Reigan P; Siegel D; Chilloux A; Ross D; Moody CJ
J Med Chem; 2007 Nov; 50(23):5780-9. PubMed ID: 17944451
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo.
Gustafson DL; Siegel D; Rastatter JC; Merz AL; Parpal JC; Kepa JK; Ross D; Long ME
J Pharmacol Exp Ther; 2003 Jun; 305(3):1079-86. PubMed ID: 12649308
[TBL] [Abstract][Full Text] [Related]
5. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.
Dehn DL; Siegel D; Swann E; Moody CJ; Ross D
Mol Pharmacol; 2003 Sep; 64(3):714-20. PubMed ID: 12920209
[TBL] [Abstract][Full Text] [Related]
6. Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase.
Newsome JJ; Swann E; Hassani M; Bray KC; Slawin AM; Beall HD; Moody CJ
Org Biomol Chem; 2007 May; 5(10):1629-40. PubMed ID: 17571194
[TBL] [Abstract][Full Text] [Related]
7. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.
Winski SL; Faig M; Bianchet MA; Siegel D; Swann E; Fung K; Duncan MW; Moody CJ; Amzel LM; Ross D
Biochemistry; 2001 Dec; 40(50):15135-42. PubMed ID: 11735396
[TBL] [Abstract][Full Text] [Related]
9. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
[TBL] [Abstract][Full Text] [Related]
11. ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK.
González-Aragón D; Alcaín FJ; Ariza J; Jódar L; Barbarroja N; López-Pedrera C; Villalba JM
Chem Biol Interact; 2010 Jul; 186(2):174-83. PubMed ID: 20433816
[TBL] [Abstract][Full Text] [Related]
12. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.
Siegel D; Gustafson DL; Dehn DL; Han JY; Boonchoong P; Berliner LJ; Ross D
Mol Pharmacol; 2004 May; 65(5):1238-47. PubMed ID: 15102952
[TBL] [Abstract][Full Text] [Related]
13. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
Colucci MA; Moody CJ; Couch GD
Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
[TBL] [Abstract][Full Text] [Related]
14. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
15. Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.
Yan C; Dufour M; Siegel D; Reigan P; Gomez J; Shieh B; Moody CJ; Ross D
Biochemistry; 2011 Aug; 50(31):6678-88. PubMed ID: 21718050
[TBL] [Abstract][Full Text] [Related]
16. Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target.
Yan C; Shieh B; Reigan P; Zhang Z; Colucci MA; Chilloux A; Newsome JJ; Siegel D; Chan D; Moody CJ; Ross D
Mol Pharmacol; 2009 Jul; 76(1):163-72. PubMed ID: 19364812
[TBL] [Abstract][Full Text] [Related]
17. Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.
Hassani M; Cai W; Koelsch KH; Holley DC; Rose AS; Olang F; Lineswala JP; Holloway WG; Gerdes JM; Behforouz M; Beall HD
J Med Chem; 2008 Jun; 51(11):3104-15. PubMed ID: 18457384
[TBL] [Abstract][Full Text] [Related]
18. Methoxylation of resveratrol: effects on induction of NAD(P)H quinone-oxidoreductase 1 (NQO1) activity and growth inhibitory properties.
Zhang W; Go ML
Bioorg Med Chem Lett; 2011 Feb; 21(3):1032-5. PubMed ID: 21215623
[TBL] [Abstract][Full Text] [Related]
19. Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism.
Cullen JJ; Hinkhouse MM; Grady M; Gaut AW; Liu J; Zhang YP; Weydert CJ; Domann FE; Oberley LW
Cancer Res; 2003 Sep; 63(17):5513-20. PubMed ID: 14500388
[TBL] [Abstract][Full Text] [Related]
20. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
Siegel D; Shieh B; Yan C; Kepa JK; Ross D
J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
